Aggressive undifferentiated colon carcinoma producing granulocyte-colony stimulating factor: Report of a case

Matsuda, Akihisa; Sumii, Koji; Matsutani, Takeshi; Maruyama, Hiroshi; Miyamoto, Masayuki; Yokoyama, Tadashi; Suzuki, Seiji; Suzuki, Hideyuki; Tajiri, Takashi

doi:10.1007/s00595-008-3941-1

Cited by 17 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, clinical case reports of G‐CSF‐secreting cancers of colon and rectum describe patients presenting with large tumors and distal metastases . Despite surgical resection resulting in reduced G‐CSF plasma levels, the overall survival of these patients is poor implying oncogenic functions for G‐CSF . The aforementioned studies thus propose differential roles for GM‐CSF and G‐CSF in cancers of colon and rectum.…”

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

“…Moreover, patients with colorectal cancers whose tumors test positive for GM‐CSF/GM‐CSFR show improved overall 5‐year survival . In contrast, clinical case reports of G‐CSF‐secreting cancers of colon and rectum describe patients presenting with large tumors and distal metastases . Despite surgical resection resulting in reduced G‐CSF plasma levels, the overall survival of these patients is poor implying oncogenic functions for G‐CSF .…”

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

See 1 more Smart Citation

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Aliper¹,

et al. 2014

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.

show abstract

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

Section: Tumors Secreting G‐/gm‐csfmentioning

confidence: 99%

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Aliper¹,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…NECs mostly occur in the rectum, the caecum or the sigmoid colon 7,8,12 . At the time of diagnosis, the tumor usually has a diameter> 5 cm [13] and the disease is locally and systematically advanced [2,14]. Specifically, in 90% of cases, the stage of disease is Dukes' C & D 11 , while in 87% there is a presence of metastases already 8,15 , as in the current case.…”

Section: Discussionmentioning

confidence: 51%

Polymetastatic highly aggressive Small Cell Undifferentiated Neuroendocrine Carcinoma of Ascending Colon

Ioannidis¹,

Chatzidelios²,

Mantzoros³

et al. 2019

CIRUE

View full text Add to dashboard Cite

Neuroendocrine carcinoma (NEC) of the colon is a rare and very aggressive tumor with poor prognosis. The current case report presents a 53-year-old male with a 6 cm × 10 cm ascending colon carcinoma, causing large intestine obstruction, with simultaneous multiple hepatic metastases and peritoneal carcinomatosis. Surgical resection of the primary tumor was performed, because of the bowel obstruction, to ameliorate the symptoms before the onset of chemotherapy. Histopathology revealed that the tumor was a small-cell undifferentiated NEC. During the post0operative period, the patient presented pulmonary metastases, and on the 36th post-operative day, death occurred due to respiratory failure.

show abstract

“…In addition, the 5‐year overall survival rate of CRC patients whose tumors tested positive for GM‐CSF/GM‐CSFR has improved [ 146 ]. In contrast, patients with colon and rectal cancers accompanied by G‐CSF‐secretion have shown a high ratio of large tumors and distal metastases, and the overall survival of these patients is poor, suggesting oncogenic effects for G‐CSF [ 147 , 148 ].…”

Section: Prognostic Role Of G‐csf / Gm‐c...mentioning

confidence: 99%

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors

Liu

Hoffman

et al. 2022

FEBS Open Bio

View full text Add to dashboard Cite

There are two types of abnormal hematopoiesis in solid tumor occurrence and treatment: pathological hematopoiesis, and myelosuppression induced by radiotherapy and chemotherapy. In this review we primarily focus on the abnormal pathological hematopoietic differentiation in cancer induced by tumor‐released granulocyte colony‐stimulating factor (G‐CSF) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). As key factors in hematopoietic development, G‐CSF/GM‐CSF are well‐known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Here, dysregulated hematopoiesis induced by G‐CSF/GM‐CSF in solid tumors and its mechanism are summarized, and the prognostic value of G‐CSF/GM‐CSF‐associated dysregulated hematopoiesis for tumor metastasis is also briefly highlighted.

show abstract

Aggressive undifferentiated colon carcinoma producing granulocyte-colony stimulating factor: Report of a case

Cited by 17 publications

References 15 publications

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

A role for G‐CSF and GM‐CSF in nonmyeloid cancers

Polymetastatic highly aggressive Small Cell Undifferentiated Neuroendocrine Carcinoma of Ascending Colon

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors

Contact Info

Product

Resources

About